Walleye Capital
XERS icon

Walleye Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Walleye Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-623,962
Closed -$5.08M – 5212
2025
Q3 		$5.08M Buy
623,962
+380,687
+156% +$2.53M 0.02% 917
2025
Q2 		$1.14M Sell
243,275
-448,444
-65% -$2.05M ﹤0.01% 1948
2025
Q1 		$3.8M Buy
+691,719
New +$2.79M 0.02% 964
2024
Q4 		– Sell
-1,121,738
Closed -$3.2M – 5652
2024
Q3 		$3.2M Buy
+1,121,738
New +$2.88M 0.01% 1528
2024
Q1 		– Sell
-35,927
Closed -$84.4K – 5960
2023
Q4 		$84.4K Sell
35,927
-88,763
-71% -$164K ﹤0.01% 4117
2023
Q3 		$232K Buy
+124,690
New +$286K ﹤0.01% 3437
2020
Q2 		– Sell
-113,269
Closed -$221K – 1014
2020
Q1 		$221K Buy
+113,269
New +$487K 0.05% 420

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's XERS Position: Q4 2025 in Review

Walleye Capital sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 623,962 shares — an estimated $5.08M sold.

Walleye Capital first reported a position in XERS in Q1 2020 and held it in 7 quarters. The position peaked at $5.08M in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Walleye Capital reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 623,962 Xeris Biopharma Holdings shares in Q4 2025, an estimated $5.08M.
  • Walleye Capital first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 7 quarters.
  • Walleye Capital's Xeris Biopharma Holdings position peaked at $5.08M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.